Full Breakdown
Trade-Margin Cap on 137 Anti-Cancer Drugs Takes Effect from Nov 9 2026
By Drooid · · How we work
Core Event: 30 % Trade-Margin Ceiling Enforced
The National Pharmaceutical Pricing Authority (NPPA) has invoked Paragraph 19 of the Drugs (Prices Control) Order, 2013 to limit the trade margin that distributors, stockists and chemists may add to the maximum retail price (MRP) of 137 non-scheduled anti-cancer medicines. The ceiling—30 % of the pre-tax MRP, equivalent to a 42.86 % markup on the price to stockist or distributor (PTS/PTD)—becomes mandatory on November 9 2026. Manufacturers have seven days from the Gazette notification (issued October 17 2026) to submit revised MRPs, after which hospitals and retailers must display the new prices and charge patients accordingly.
Background & Context
India’s drug-price regime distinguishes “scheduled” medicines, whose prices are fixed under the National List of Essential Medicines, from “non-scheduled” drugs that can be priced freely. Non-scheduled anti-cancer drugs account for roughly 82 % of the oncology market and have attracted scrutiny for mark-ups ranging from 170 % to over 700 %. The Supreme Court, hearing petitions by advocate Kishan Chand Jain and practitioner Sanjay Kulshrestha, described a case where a drug with an MRP of INR27,000 was sold to retailers for INR2,700 as “broad daylight dacoity.” A 2019 pilot capped margins on 42 cancer drugs, achieving price cuts of up to 91 % across 526 brands. The current order expands that framework, based on recommendations from an expert committee under the Directorate General of Health Services (DGHS).
Data & Statistics
- 137 drugs covered, including nivolumab, pembrolizumab, palbociclib and osimertinib.
- Expected price reductions of 20 %–70 %.
- NPPA estimates annual patient savings of about INR2,500 crore.
- The oncology market’s annual turnover is roughly INR12,500 crore, with non-scheduled drugs forming the bulk.
Official Statements & Responses
The authority clarified that the manufacturer’s price remains unchanged; the cap only trims the margin added by downstream intermediaries. Manufacturers must maintain current production levels, obtain prior permission for any reduction, and submit detailed price lists through the Integrated Pharmaceutical Database Management System (IPDMS). State drug controllers will monitor compliance, and the NPPA may recover any excess amounts charged.
Verbatim Quotes
- “Affordability must be viewed across the entire cancer-care pathway, from screening and diagnosis to treatment,” — Mayur Sirdesai
- “Price of these medicines even after margin cap will remain out of reach of many people.” — K.M. Gopakumar
What’s Next
- Manufacturers must file revised MRPs with NPPA and state drug controllers within seven days of the Gazette notification.
- Revised price lists are to be posted on company websites, circulated to retailers, and uploaded to the NPPA’s “Pharma Sahi Daam” mobile app.
- Hospitals and pharmacies must display the new rates from November 9 2026 and report violations.
- Ongoing oversight includes audits of patient-assistance programme exemptions and enforcement actions for non-compliance, including recovery of overcharged amounts with interest.
The cap represents the government’s most extensive price-regulation effort in the oncology sector to date, targeting excessive trade margins while seeking to preserve manufacturing incentives and drug availability.